A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)

Overview of attention for article published in Frontiers in Pharmacology, February 2024

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 7,248 followers.

RT @3stars67664378: 💉抗体薬物複合体製剤ADCは神経毒性リスクを増加させる？ - ⚡️FAERSの解析 - いずれの製剤も末梢神経障害、脳出血、味覚障害、ギランバレー症候群などでシグナル検出 https://t.co/cZSWfLJS8q

27 Feb 2024

Reply Repost Favourite

💉抗体薬物複合体製剤ADCは神経毒性リスクを増加させる？ - ⚡️FAERSの解析 - いずれの製剤も末梢神経障害、脳出血、味覚障害、ギランバレー症候群などでシグナル検出 https://t.co/cZSWfLJS8q

27 Feb 2024

Reply Repost Favourite

New Research: A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS) https://t.co/vvjQp2fddK #pharmacology

07 Feb 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.